Researcher
Nick Geukens
- Disciplines:Laboratory medicine, Medical biotechnology, Regenerative medicine, Other basic sciences, Other health sciences, Drug discovery and development, Pharmaceutics, Other medical and health sciences
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From15 May 2019 → Today - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Sep 2009 → 14 May 2019 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From14 Jul 2008 → 31 Aug 2009 - Laboratory of Molecular Bacteriology (Rega Institute) (Division)
Member
From1 Oct 1999 → 13 Jul 2008
Projects
1 - 10 of 23
- Next generation immunotherapy solutions against macrophages to overcome cancer immuno-resistanceFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- A novel targeted therapy to treat bleeding in patients with a left ventricular assist device.From1 May 2023 → TodayFunding: IOF - mandates
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- When size matters: a platform to study molecular interactions and multimerisationFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Next-generation DNA vectors to improve efficacy, precision and accessibility of antibody gene transferFrom15 Mar 2022 → 14 Mar 2024Funding: BOF - various
- Targeted mass spectrometry-based quantification of autoantibodies in systemic rheumatic diseasesFrom1 Oct 2021 → 30 Sep 2023Funding: FWO Applied Biomedical Research (TBM)
- Rational design of biologics for therapeutic development (FoldCo)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Why dose lung damage sometimes continue to worsen after the body seems to have cleared the SARS-CoV-2 virus?From1 Oct 2021 → 31 Mar 2023Funding: Foreign private sponsor - undefined
- Unraveling of protective innate and adaptive immune responses to SARS-CoV-2 in the setting of HCoV crossreactivityFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
Publications
41 - 50 of 65
- Antibody-modified iron oxide nanoparticles for efficient magnetic isolation and flow cytometric determination of L. pneumophila(2015)
Authors: Maarten Bloemen, Luc De Meester, Ann Gils, Nick Geukens, Thierry Verbiest
Pages: 1439 - 1446 - Multifunctional iron oxide nanoparticles for biomedical applications(2015)
Authors: Maarten Bloemen, Carla Denis, Thomas Van Stappen, Luc De Meester, Nick Geukens, Ann Gils, Thierry Verbiest
- Multifunctional iron oxide nanoparticles for biomedical applications(2015)
Authors: Maarten Bloemen, Thomas Van Stappen, Luc De Meester, Nick Geukens, Ann Gils, Thierry Verbiest
Number of pages: 8 - Transferability of antibody pairs from ELISA to fiber optic-surface plasmon resonance for infliximab detection(2015)
Authors: Thomas Van Stappen, Jiadi Lu, Maarten Bloemen, Nick Geukens, Dragana Spasic, Filip Delport, Thierry Verbiest, Jeroen Lammertyn, Ann Gils
Number of pages: 7 - Transferability of antibody pairs from ELISA to fiber optic-surface plasmon resonance for infliximab detection(2015)
Authors: Thomas Van Stappen, Jiadi Lu, Maarten Bloemen, Nick Geukens, Dragana Spasic, Filip Delport, Thierry Verbiest, Jeroen Lammertyn, Ann Gils
- Two-Step Directional Surface Modification of Iron Oxide Nanoparticles with Protected Siloxanes(2015)
Authors: Maarten Bloemen, Ben Sutens, Ward Brullot, Ann Gils, Nick Geukens, Thierry Verbiest
Pages: 50 - 53 - Selective protein purification by PEG-IDA-functionalized iron oxide nanoparticles(2015)
Authors: Maarten Bloemen, Louis Vanpraet, Matthias Ceulemans, Tatjana Vogt, Koen Clays, Nick Geukens, Ann Gils, Thierry Verbiest
Pages: 66549 - 66553 - Heterobifunctional PEG Ligands for Bioconjugation Reactions on Iron Oxide Nanoparticles(2014)
Authors: Maarten Bloemen, Thomas Van Stappen, Pieter Willot, Jeroen Lammertyn, Guy Koeckelberghs, Nick Geukens, Ann Gils, Thierry Verbiest
- Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization(2014)
Authors: Ann Gils, Niels Vande Casteele, Marlies Van de Wouwer, Séverine Vermeire, Nick Geukens, Paul Declerck
Pages: 669 - 73 - Prevention of Recurrent Clostridium difficile Infection by Neutralizing Monoclonal Antibodies in a Hamster Relapse Model(2014)
Authors: Dominiek Staelens, Marlies Van de Wouwer, Els Brouwers, Silvia Caluwaerts, Pieter Rottiers, Peter Vanhoenacker, Nick Geukens, Paul Declerck, Marc Ferrante, Séverine Vermeire, et al.
Pages: S250 - S250
Patents
1 - 5 of 5
- Screening and sorting of single cells (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Screening and sorting of single cells (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1